Nonalcoholic fatty liver disease and the metabolic syndrome.
about
MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolismComorbidities and Metabolic Derangement of NAFLDA targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidationA cohort study of serum bilirubin levels and incident non-alcoholic fatty liver disease in middle aged Korean workersTriglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohortDysregulation of sterol regulatory element binding protein-1c in livers of morbidly obese women is associated with altered suppressor of cytokine signaling-3 and signal transducer and activator of transcription-1 signaling.Histamine regulation in glucose and lipid metabolism via histamine receptors: model for nonalcoholic steatohepatitis in miceAssociation Between Elevated Liver Enzymes and Metabolic Syndrome Among Thai Adults.Prevalence of fatty liver disease and its risk factors in the population of South China.Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study.Upper limits of normal for serum alanine aminotransferase levels in Chinese Han population.Transcription factor Nrf2 regulates SHP and lipogenic gene expression in hepatic lipid metabolism.Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.Exacerbating effects of human parvovirus B19 NS1 on liver fibrosis in NZB/W F1 mice.Stearoyl-CoA desaturase and its relation to high-carbohydrate diets and obesity.Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α.Adiponectin, a key adipokine in obesity related liver diseasesMechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats.Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular riskNutrition and physical activity in NAFLD: an overview of the epidemiological evidence.Nonalcoholic fatty liver disease is associated with coronary artery calcium score in diabetes patients with higher HbA1c.Non-alcohol fatty liver disease in Asia: Prevention and planning.Non-alcoholic fatty liver disease among sasang constitutional types: a population-based study in KoreaPrevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndromeGenetic Dissection of Tissue-Specific Apolipoprotein E Function for Hypercholesterolemia and Diet-Induced Obesity.Raspberry ketone protects rats fed high-fat diets against nonalcoholic steatohepatitis.High fat diet-induced inflammation and oxidative stress are attenuated by N-acetylneuraminic acid in rats.BNip3 regulates mitochondrial function and lipid metabolism in the liver.First-degree relatives of patients with type 2 diabetes mellitus and risk of non-alcoholic Fatty liver disease.Role of CYP2E1 in mitochondrial dysfunction and hepatic tissue injury in alcoholic and non-alcoholic diseases.Hydroxypropyl methylcellulose, a viscous soluble fiber, reduces insulin resistance and decreases fatty liver in Zucker Diabetic Fatty rats.Diabetic and dyslipidaemic morbidly obese exhibit more liver alterations compared with healthy morbidly obeseAdipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease.Transient prenatal androgen exposure produces metabolic syndrome in adult female ratsTreating nonalcoholic fatty liver disease.Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern.Non-alcoholic fatty liver disease and the metabolic syndrome: an update.GLUT2 proteins and PPARγ transcripts levels are increased in liver of ovariectomized rats: reversal effects of resistance training.Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial.
P2860
Q24629354-2A5563FC-6254-4FF0-B67E-FF76257812F3Q26777147-BD83D745-9CA4-43A8-A892-95F9657CC402Q28585589-CD5D19FE-9ED7-4F11-8EEE-B1DB984AE5C2Q28729949-B5D5A21E-5454-4D88-8677-5FB153DBBE9AQ33691736-057B0CAB-8624-44B0-BA4D-B0BDCC58EC2FQ33746400-A94D9100-BF1D-4844-B145-1F55B67FB2CDQ34033317-BDEA1BC0-4AA6-4FFC-8E1B-34926CEC31ABQ34065848-4C22E852-77FE-4C79-8124-5CBA2A629CB8Q34382961-60F9EB77-B0E3-4997-92B2-AC3E0542C1F8Q34406289-3FC93177-7596-4474-8608-C14B0B2EC524Q34409744-EFC9812F-A505-4C72-A253-7B5D9EB8F04CQ34425926-13BCB825-52B4-4121-9C7D-399FF0F391A8Q34758939-8FCCEA88-3442-424F-9C65-B387AA0C4DEEQ34808812-4308400A-0AF4-40F3-9E61-293C62EC01A5Q34929006-4CF14563-53DC-4214-B47D-8185AF3F5D9BQ35028578-968326BE-58AA-44CC-B8A8-C3A69BCEE340Q35061908-74F69853-E992-42AE-A4D4-EDDE5D2E9F69Q35078019-934871D7-13AF-4878-8C95-8098E29AECD1Q35171570-C70607A0-BCE1-4EAD-BD8A-0F284C7FE501Q35178073-1669E89F-993B-461F-99B4-1053F4699BC0Q35258097-2D5DA4DA-6AF5-41D5-A6A8-DE4EA2B98415Q35819344-2731981F-DBF0-4708-8735-60F69CD45CF8Q35835264-6C8F35DB-42D7-482F-BB16-D88B6C9E306FQ35841222-80E8A699-F037-47BD-A2C7-DE0A06FFDA72Q35872059-3B10EA6F-BDE2-4214-B05C-3DC1F6F3AB94Q35875732-4ABF30A0-EF59-4F14-BC5B-51D4A8F65157Q35916987-89B7CB69-6333-4B45-86E7-8D852228F4B2Q36203090-FC2A9121-C431-43A0-8846-C4BB535FCA06Q36210910-25989902-123A-4A8C-A870-3017F003519FQ36501848-CB529047-2C52-431A-81C5-BA1D8587635DQ36590615-45053229-05AB-4BE4-BADC-9EC93F2C337FQ36591525-C9511D68-7A22-4E0D-81C6-B52F6B4CAA2EQ36713843-89F2842F-A2A7-4B8B-A9A5-B85E5699D87FQ36748514-5E1EF4F5-FFEE-4405-915E-ED3E36F95AE3Q36846127-7C919FD8-5507-4D8F-9801-73E1972BAF12Q36962239-A2A45A63-B01E-48D3-A5B7-9B6BDC9BA8DFQ37003731-FFF3CD0B-DD97-4E46-97FF-CD1C6C16CF10Q37054351-2D94912F-B8A7-428A-9AF8-9E8D93C1F1D2Q37160827-A0C01B20-F00D-402E-BABB-AFA6A8D65D85Q37352458-D0B21CE7-35B7-4A3F-93C5-D3545D117C5A
P2860
Nonalcoholic fatty liver disease and the metabolic syndrome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Nonalcoholic fatty liver disease and the metabolic syndrome.
@ast
Nonalcoholic fatty liver disease and the metabolic syndrome.
@en
type
label
Nonalcoholic fatty liver disease and the metabolic syndrome.
@ast
Nonalcoholic fatty liver disease and the metabolic syndrome.
@en
prefLabel
Nonalcoholic fatty liver disease and the metabolic syndrome.
@ast
Nonalcoholic fatty liver disease and the metabolic syndrome.
@en
P1476
Nonalcoholic fatty liver disease and the metabolic syndrome.
@en
P2093
Giulio Marchesini
Rebecca Marzocchi
P304
P356
10.1097/01.MOL.0000174153.53683.F2
P577
2005-08-01T00:00:00Z